Table 3

Matched pair analysis comparing survival among patients who underwent allogeneic HSCT for first chronic phase chronic myeloid leukemia from 1999 to 2004

VariablenRelative risk of death (95% CI)P
Main effect 
    No imatinib 236 1.00*  
    Imatinib 143 0.48 (0.31-0.75) .001† 
VariablenRelative risk of death (95% CI)P
Main effect 
    No imatinib 236 1.00*  
    Imatinib 143 0.48 (0.31-0.75) .001† 

Matched variables include (1) time from diagnosis to transplant plus or minus 3 months, (2) HLA match, (3) graft type, and (4) sex match versus other. There are 143 imatinib cases for which matched controls were identified.

CI indicates confidence interval.

*

Reference group.

†

One degree of freedom.

View Large